ClinicalTrials.gg
RecruitingNCT06581146EXCELUpdated Sep 30, 2026

A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition

An observational study in X-Linked Myotubular Myopathy, sponsored by Astellas Gene Therapies. Recruiting at 11 sites in 3 countries. Open to male participants aged Up to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Astellas Gene Therapies (part of Astellas Pharma Inc) · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
Up to 17 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Myopathies, Structural, Congenital with a site in United States — 4 open to participants now, 6 under way, 1 of them phase 3. Myopathies, Structural, Congenital · United States.

Started
2025
with 2 others
Observational
8 of 13
2 open now
Registered
10th of 13
by date
Lead sponsor
5 of 13
Astellas Gene Therapies

Among the 13 studies in Myopathies, Structural, Congenital with a site in United States, this one is one of 3 that started in 2025, is one of 8 observational ones, and was the 10th registered.

Myopathies, Structural, Congenital

24 studies on the registry are indexed under Myopathies, Structural, Congenital; 10 are open to participants now.

Browse Myopathies, Structural, Congenital studies →

Open to participants now

4 of the 13 studies in Myopathies, Structural, Congenital with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Myopathies, Structural, Congenital studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 7 take children under 18; 2 take healthy volunteers.

This study: Up to 17 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Myopathies, Structural, Congenital with a site in United States, or all of them as a file.
02

Study summary

XLMTM (X-linked myotubular myopathy) is a serious genetic muscle condition. It is caused by changes in the MTM1 gene which stops or slows down normal muscle development, causing severe muscle weakness. There is currently no cure for XLMTM. Ongoing care is needed to manage symptoms and prevent further medical problems from this condition.

Recent research shows that individuals with XLMTM often have reduced bile flow which can affect liver and gallbladder health. Bile is a liquid made in the liver that helps digest fat. Ongoing liver health checks may help with the routine care of people with XLMTM.

There is a need to understand liver problems that develop in individuals with XLMTM over time. The main aim of the study is to learn how many boys with XLMTM have new cases of liver problems during the study.

This study is about collecting information only. This is known as an observational study. The individual's doctor decides on treatment, not the study sponsor (Astellas).

In this study, boys under 18 diagnosed with XLMTM will be followed for about 1 year. The health of their liver and gallbladder will be checked about every 6 weeks. This can be done at home, if preferred. A scan called a Fibroscan (also known as transient elastography) will check for signs of scarring in the liver (fibrosis) and the build-up of lipids. It is suggested that each boy will have a Fibroscan when they start the study and another scan when they complete the study.

This study will help understand liver, gallbladder, and bile duct issues in individuals with XLMTM over time. The goal is to improve their care and provide information to use in future clinical studies.

03

Conditions studied

  • X-Linked Myotubular Myopathy

Keywords

  • XLMTM
  • Hepatobiliary
04

Who can participate

Ages eligible
Up to 17 Years
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Approximately 50 male participants \< 18 years of age with genetically confirmed XLMTM will be enrolled at specialist sites.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a diagnosis of XLMTM resulting from a genetically confirmed mutation in the MTM1 gene based on genetic test reports.
  • Participant requires some mechanical ventilatory support (e.g., ranging from 24 hours per day full-time mechanical ventilation, to non-invasive support such as continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) during sleeping hours)
  • Participant (as applicable) and/or parent(s)/carer is willing to comply with the recommended schedule of assessments.

Exclusion criteria

Exclusion Criteria:

  • Participant is currently enrolled in an interventional study designed to treat XLMTM.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants with XLMTM

    Pediatric and adolescent participants with XLMTM.

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No investigational drug will be administered to participants in this study.

06

What researchers measure

Primary outcomes

  1. Incidence rate of cholestasis

    Calculated as the number of new cases of cholestasis over 48 weeks divided by total duration of follow-up for enrolled participants.

    Time frame: Up to Week 48

  2. Point prevalence of cholestasis

    Point prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis prior to Day 1 (baseline).

    Time frame: Day 1

  3. Prevalence of cholestasis

    Prevalence of cholestasis is defined as the proportion of participants who have had at least 1 case of cholestasis within 1 year of Day 1 (baseline).

    Time frame: Up to 1 year

Secondary outcomes

  1. Genetic variants of MTM1

    The association between genetic variants of MTM1 and cholestasis will be evaluated.

    Time frame: Up to Week 48

  2. Risk of cholestasis temporarily associated with environmental modifiers

    Medication use, immunization history, infectious disease history and dietary habits will be collected.

    Time frame: Up to Week 48

  3. Hospitalizations

    Frequency and reason for hospitalizations will be collected.

    Time frame: Up to Week 48

  4. Duration of Hospitalizations

    Duration of hospitalization visits will be collected.

    Time frame: Up to Week 48

  5. Emergency room visits

    Frequency and reason for visit will be collected.

    Time frame: Up to Week 48

  6. Hepatology specialist visits

    Frequency and reason for visit will be collected.

    Time frame: Up to Week 48

  7. Scheduled/unscheduled office visits

    Frequency and reason for visit will be collected.

    Time frame: Up to Week 48

  8. Non-study-specified home healthcare visits

    Frequency and reason for visit will be collected.

    Time frame: Up to Week 48

  9. Surgeries/procedures

    Frequency and type will be collected.

    Time frame: Up to Week 48

07

Study locations

11 of 11 sites recruiting
  • UCLA Neurological Services
    Santa Monica, California 90401-2072, United States
    Recruiting
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
    Recruiting
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
    Recruiting
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
    Recruiting
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
    Recruiting
  • University of Utah
    Salt Lake City, Utah 84112, United States
    Recruiting
  • Site CA15001
    Toronto, Ontario, Canada
    Recruiting
  • Site GB44006
    Leeds, United Kingdom
    Recruiting
  • Site GB44003
    London, United Kingdom
    Recruiting
  • Site GB44005
    Oxford, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2024
First posted
Sep 3, 2024
StartActual
May 19, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06581146
Responsible party
Sponsor
First posted
Sep 3, 2024
Start date
May 19, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Astellas Gene Therapies
Contact
Astellas.registration@astellas.com
800-888-7704
Medical Director
study director · Astellas Gene Therapies

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion